Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17127221 | CELL ENCAPSULATION DEVICE COMPRISING A PANCREATIC PROGENITOR CELL POPULATION | December 2020 | April 2023 | Allow | 28 | 1 | 0 | Yes | No |
| 17126449 | PERFUSABLE-TYPE DUAL PROXIMAL TUBULE CELL CONSTRUCT AND PRODUCING METHOD THEREOF FOR APPLYING IN VITRO ARTIFICIALRENAL TISSUE MODEL AND RENAL CELL THERAPY | December 2020 | January 2024 | Allow | 37 | 1 | 1 | No | No |
| 17125837 | Cancellous Bone Product Including Viable Osteogenic Cells | December 2020 | August 2023 | Allow | 32 | 1 | 0 | No | No |
| 17121639 | METHODS AND COMPOSITIONS FOR TREATING UREA CYCLE DISORDERS | December 2020 | October 2021 | Allow | 10 | 1 | 1 | Yes | No |
| 17120626 | Placental Tissue Grafts And Improved Methods Of Preparing And Using The Same | December 2020 | April 2023 | Allow | 28 | 1 | 0 | No | No |
| 17104202 | CONDITIONED MEDIUM FROM HUMAN ADULT LIVER STEM CELLS AND ITS USE IN THE TREATMENT OF LIVER DISORDERS | November 2020 | June 2023 | Allow | 31 | 1 | 0 | Yes | No |
| 16953709 | METHOD OF HARVESTING MESENCHYMAL STEM CELLS FROM CORD-PLACENTA JUNCTION | November 2020 | January 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17250058 | PRODUCING METHOD OF THE COLLAGEN-LAMININ MATRIX FOR HEALING ULCERS, BURNS AND WOUNDS OF A HUMAN SKIN | November 2020 | April 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 17053200 | METHODS FOR EXP ANDING ADIPOSE-DERIVED STEM CELLS | November 2020 | October 2024 | Abandon | 47 | 0 | 1 | No | No |
| 17052854 | ENHANCEMENT OF FIBROBLAST PLASTICITY FOR TREATMENT OF DISC DEGENERATION | November 2020 | August 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17088090 | LUNG AND AIRWAY PROGENITORS GENERATED FROM HUMAN PLURIPOTENT STEM CELLS AND RELATED TREATMENTS | November 2020 | April 2023 | Allow | 29 | 2 | 0 | No | No |
| 17083045 | METHOD OF MAKING LIPIDS WITH IMPROVED COLD FLOW PROPERTIES | October 2020 | December 2023 | Allow | 37 | 2 | 0 | No | No |
| 17077698 | METHOD OF TREATING GRAFT VERSUS HOST DISEASE | October 2020 | July 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17073169 | METHOD FOR PRODUCING HYPOPHYSIS PRECURSOR TISSUE | October 2020 | July 2023 | Allow | 33 | 1 | 1 | Yes | No |
| 17044744 | METHODS OF TREATING CEREBRAL PALSY AND HYPOXIC-ISCHEMIC ENCEPHALOPATHY USING HUMAN UMBILICAL CORD TISSUE-DERIVED MESENCHYMAL STROMAL CELLS | October 2020 | May 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17043270 | CARDIOMYOCYTE PREPARATION AND PREPARATION METHOD THEREFOR AND USE THEREOF | September 2020 | April 2024 | Allow | 43 | 1 | 1 | No | No |
| 17022807 | MESENCHYMAL STROMAL CELLS AND USES RELATED THERETO | September 2020 | May 2024 | Allow | 44 | 4 | 0 | No | No |
| 17009797 | Methods for Preparing Therapeutically Active Cells Using Microfluidics | September 2020 | April 2021 | Allow | 8 | 1 | 0 | Yes | No |
| 17010346 | METHODS OF ENHANCING STEM CELL DIFFERENTIATION INTO BETA CELLS | September 2020 | February 2025 | Abandon | 53 | 2 | 1 | No | No |
| 16994061 | METHODS OF DETERMINING THE SUITABILITY OF CULTURED THYMUS TISSUE FOR IMPLANTATION INTO HUMANS AND ASSOCIATED METHODS OF USE | August 2020 | August 2024 | Allow | 48 | 2 | 1 | No | No |
| 16992175 | METHOD FOR PREPARING AN IRRADIATED PLATELET LYSATE | August 2020 | October 2024 | Abandon | 50 | 1 | 1 | No | No |
| 16992136 | METHOD FOR INDUCING OLIGODENDROCYTE PRECURSOR CELLS FROM OCT4-INDUCED HUMAN SOMATIC CELLS THROUGH DIRECT REPROGRAMMING | August 2020 | October 2022 | Allow | 26 | 0 | 0 | Yes | No |
| 16969600 | METHOD FOR PREPARING AN IRRADIATED PLATELET LYSATE | August 2020 | December 2024 | Allow | 52 | 1 | 1 | Yes | No |
| 16968436 | CHONDROCYTE PROLIFERATION PROMOTER, CHONDROCYTE PROLIFERATION PROMOTION METHOD, SCREENING METHOD FOR CHONDROCYTE PROLIFERATION PROMOTERS | August 2020 | April 2024 | Abandon | 44 | 1 | 1 | No | No |
| 16988117 | ENHANCING THE EFFECT OF CAR-ENGINEERED T CELLS BY MEANS OF NUCLEIC ACID VACCINATION | August 2020 | August 2024 | Allow | 49 | 4 | 0 | Yes | No |
| 16939204 | BIOMATERIALS FOR BIOLOGICAL TISSUE REPAIR | July 2020 | February 2025 | Allow | 55 | 4 | 0 | Yes | No |
| 16940090 | HUMAN PLURIPOTENT STEM CELL-BASED SCREENING FOR SMOOTH MUSCLE CELL DIFFERENTIATION AND DISEASE | July 2020 | May 2025 | Allow | 57 | 3 | 1 | Yes | No |
| 16937777 | HUMAN HEPATOCYTES AND USES THEREOF | July 2020 | April 2021 | Allow | 9 | 1 | 1 | Yes | No |
| 16934333 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | July 2020 | February 2021 | Allow | 7 | 1 | 0 | Yes | No |
| 16926436 | EDITING OF CCR2 RECEPTOR GENE TO PROTECT AGAINST HIV INFECTION | July 2020 | July 2023 | Allow | 36 | 1 | 0 | Yes | No |
| 16912586 | SOLUBILIZATION OF ANTIGEN COMPONENTS FOR REMOVAL FROM TISSUES | June 2020 | November 2022 | Allow | 28 | 1 | 0 | Yes | No |
| 16956575 | EXOSOME ACTIVE FORMULATION FOR PROMOTING ENDOTHELIAL CELL ANGIOGENESIS, AND PREPARATION METHOD AND APPLICATION | June 2020 | February 2021 | Allow | 8 | 1 | 0 | Yes | No |
| 16771927 | EXTRACELLULAR VESICLES PURIFIED FROM DRIED BLOOD CARDS | June 2020 | April 2024 | Allow | 46 | 1 | 0 | Yes | No |
| 16887720 | CONCURRENT ACTIVATION OF REGENERATIVE AND TOLEROGENIC PROCESSES BY FIBROBLAST-BASED COMPOSITIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | May 2020 | September 2023 | Allow | 40 | 1 | 1 | Yes | No |
| 16853569 | Therapeutics Using Adipose Cells and Cell Secretions | April 2020 | April 2023 | Abandon | 36 | 1 | 0 | No | No |
| 16753530 | METHODS AND COMPOSITIONS FOR TREATING UREA CYCLE DISORDERS, IN PARTICULAR OTC DEFICIENCY | April 2020 | March 2022 | Abandon | 23 | 0 | 1 | No | No |
| 16649056 | TISSUE CONSTRUCT, METHODS OF PRODUCING AND USING THE SAME | March 2020 | January 2025 | Allow | 58 | 3 | 1 | Yes | No |
| 16639427 | Ultrathin Interfacial Layer on a Hydrogel to Direct its Surface Properties and Cell Adhesion | February 2020 | June 2023 | Allow | 40 | 1 | 1 | No | No |
| 16785756 | Muscle Derived Cells for the Treatment of Gastro-Esophageal Pathologies and Methods of Making and Using the Same | February 2020 | January 2022 | Allow | 23 | 1 | 0 | No | No |
| 16780050 | Precursor Cells Of Induced Pluripotent Stem Cell (IPSC)-Derived Mesenchymal Stem Cells And Method For Preparing The Same | February 2020 | June 2022 | Abandon | 28 | 3 | 1 | No | No |
| 16747736 | Methods for Reducing the Extent of Light-induced Tissue Inflammation and Injury | January 2020 | July 2023 | Abandon | 42 | 1 | 0 | No | No |
| 16746141 | ARTIFICIAL PLACENTA AND METHODS OF PREPARATION | January 2020 | October 2021 | Allow | 21 | 1 | 0 | Yes | No |
| 16631677 | METHODS OF PRODUCING MULTI-LAYERED TUBULAR TISSUE CONSTRUCTS | January 2020 | November 2024 | Allow | 58 | 1 | 1 | Yes | No |
| 16630188 | ARTIFICIAL TENDON OR LIGAMENT TISSUE PRODUCED USING THREE-DIMENSIONAL MECHANOSIGNALING CELL CULTURE SYSTEM | January 2020 | May 2023 | Allow | 40 | 1 | 1 | No | No |
| 16629070 | COMPOSITIONS AND METHODS FOR IMPROVING CARDIAC FUNCTION | January 2020 | July 2023 | Allow | 42 | 1 | 1 | Yes | No |
| 16729746 | Variable Density Tissue Graft Composition and Methods of Making and Using the Same | December 2019 | April 2023 | Abandon | 40 | 2 | 1 | Yes | No |
| 16730877 | PROCESS OF MAKING An AMNION DERIVED THERAPEUTIC COMPOSITION | December 2019 | February 2022 | Allow | 26 | 1 | 0 | Yes | No |
| 16697946 | METHODS FOR SCREENING PERSONAL CARE PRODUCTS | November 2019 | April 2022 | Allow | 28 | 1 | 0 | Yes | No |
| 16696947 | COMPOSITIONS AND METHODS FOR IMMUNE TOLERANCE | November 2019 | May 2025 | Allow | 60 | 4 | 0 | Yes | No |
| 16617130 | ENGINEERING FUNCTIONAL BONE ORGANS | November 2019 | December 2021 | Allow | 24 | 0 | 0 | No | No |
| 16614602 | METHODS FOR PREPARING A DECELLULARIZED MUSCLE SCAFFOLD | November 2019 | November 2023 | Abandon | 48 | 1 | 0 | No | No |
| 16686545 | Biodegradable Polymer Compositions | November 2019 | December 2021 | Abandon | 25 | 2 | 1 | No | No |
| 16685942 | Cancellous Bone Product Including Viable Osteogenic Cells | November 2019 | June 2022 | Allow | 31 | 1 | 0 | Yes | No |
| 16679908 | NANOFRACTION IMMUNE MODULATORS, PREPARATIONS AND COMPOSITIONS INCLUDING THE SAME, AND ASSOCIATED METHODS | November 2019 | August 2021 | Allow | 21 | 2 | 0 | Yes | No |
| 16678521 | COMPOSITIONS AND METHODS FOR OBTAINING FUNCTIONAL BASAL-LIKE CELLS | November 2019 | January 2023 | Allow | 38 | 1 | 0 | Yes | No |
| 16611035 | METHOD FOR PRODUCING DECELLULARIZED TISSUE, DECELLULARIZED TISSUE, AND APPARATUS FOR PRODUCING DECELLULARIZED TISSUE | November 2019 | November 2022 | Abandon | 36 | 0 | 1 | No | No |
| 16673651 | COMPOSITIONS INCLUDING DIFFERENT TYPES OF TRANSFER FACTOR | November 2019 | August 2021 | Allow | 21 | 2 | 0 | Yes | No |
| 16610500 | EXOSOME ACTIVE FORMULATION FOR INHIBITING ENDOTHELIAL CELL MIGRATION, AND PREPARATION METHOD AND APPLICATION | November 2019 | February 2021 | Allow | 15 | 1 | 0 | Yes | No |
| 16609063 | TISSUE CONSTRUCTS INCLUDING PANCREAS DERIVED MICROVESSEL FRAGMENTS AND RELATED METHODS | October 2019 | June 2022 | Allow | 31 | 1 | 1 | No | No |
| 16662033 | Methods for Preparing Therapeutically Active Cells Using Microfluidics | October 2019 | December 2020 | Allow | 14 | 2 | 0 | Yes | No |
| 16654933 | METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS | October 2019 | December 2021 | Allow | 26 | 1 | 0 | Yes | No |
| 16598597 | DECELLULARIZED MUSCLE MATRIX | October 2019 | August 2023 | Allow | 46 | 3 | 1 | Yes | No |
| 16495557 | GENERATION OF LUNG BUD ORGANOIDS WITH BRANCHING STRUCTURES AND USES THEREOF FOR LUNG DISEASE MODELING | September 2019 | October 2023 | Allow | 49 | 3 | 0 | No | No |
| 16555987 | Method for Treating Diabetes and Other Glucose Regulation Disorders Using Stem Cells | August 2019 | April 2021 | Allow | 19 | 1 | 0 | Yes | No |
| 16547396 | SELECTIVE NEAR-INFRARED OPTICAL IMAGING OF NECROTIC CELLS AND SIMULTANEOUS CELL FIXING AND COUNTER STAINING WITH METALLACROWN COMPLEXES | August 2019 | April 2022 | Allow | 31 | 1 | 0 | Yes | No |
| 16487117 | Product and Method for the Treatment of Bioprosthetic Tissues | August 2019 | February 2023 | Allow | 41 | 2 | 1 | No | No |
| 16483095 | STABLE THREE-DIMENSIONAL BLOOD VESSELS AND METHODS FOR FORMING THE SAME | August 2019 | November 2023 | Allow | 51 | 2 | 1 | No | No |
| 16525062 | FROZEN THERAPEUTIC DOSE AND PACKAGE | July 2019 | March 2022 | Abandon | 32 | 2 | 0 | No | No |
| 16480114 | THREE-DIMENSIONAL TISSUE BODY, METHOD FOR PRODUCING SAME, AND FORMATION AGENT FOR THREE-DIMENSIONAL TISSUE BODY | July 2019 | July 2021 | Allow | 24 | 3 | 0 | Yes | No |
| 16520020 | THREE DIMENSIONAL HETEROGENEOUSLY DIFFERENTIATED TISSUE CULTURE | July 2019 | January 2022 | Allow | 30 | 1 | 0 | Yes | No |
| 16479392 | COMPOSITION AND METHOD OF USE OF THE SAME FOR PRESERVING CELLS FOR ANALYSIS | July 2019 | September 2023 | Allow | 50 | 2 | 1 | Yes | No |
| 16513183 | METHODS FOR MAKING ACELLULAR TISSUE MATRICES | July 2019 | January 2024 | Abandon | 54 | 4 | 0 | No | No |
| 16452415 | CRYOPRESERVED ENDOCRINE CELLS THAT EXPRESS CHROMOGRANIN A | June 2019 | February 2022 | Allow | 32 | 1 | 1 | Yes | No |
| 16449867 | BONE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS, AND TREATMENTS THEREOF | June 2019 | June 2021 | Abandon | 23 | 1 | 0 | No | No |
| 16472477 | METHODS FOR GENERATING MULTIPOTENT STEM CELLS FROM TONSILLAR BIOPSIES | June 2019 | December 2023 | Allow | 54 | 2 | 1 | No | No |
| 16431593 | HUMAN CARDIAC TISSUE CONSTRUCT, RELATED METHODS AND USES | June 2019 | December 2022 | Abandon | 43 | 1 | 1 | Yes | No |
| 16429062 | METHOD FOR INDUCING OLIGODENDROCYTE PRECURSOR CELLS FROM OCT4-INDUCED HUMAN SOMATIC CELLS THROUGH DIRECT REPROGRAMMING | June 2019 | May 2020 | Allow | 11 | 0 | 0 | No | No |
| 16421191 | COMPOSITIONS AND METHODS FOR PREVENTING THE PROLIFERATION AND EPITHELIAL-MESENCHYMAL TRANSITION OF EPITHELIAL CELLS | May 2019 | November 2021 | Allow | 30 | 2 | 0 | Yes | No |
| 16421086 | LAMINATED TISSUE GRAFTS COMPOSED OF WHARTON'S JELLY AND METHODS OF MAKING AND USING THE SAME | May 2019 | November 2022 | Allow | 41 | 3 | 1 | Yes | No |
| 16463093 | ENCAPSULATED LIVER TISSUE | May 2019 | June 2022 | Allow | 37 | 1 | 0 | Yes | No |
| 16349108 | Bioprinted Hair Follicles and Uses Thereof | May 2019 | August 2023 | Allow | 51 | 2 | 1 | No | No |
| 16347939 | 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY | May 2019 | May 2022 | Allow | 37 | 1 | 1 | Yes | No |
| 16347608 | THREE-DIMENSIONAL AGED SKIN MODEL AND METHOD OF CREATING THE SAME | May 2019 | November 2021 | Abandon | 30 | 2 | 0 | No | No |
| 16339536 | COMPOSITIONS COMPRISING ADJUSTABLE CONCENTRATIONS OF GROWTH FACTORS DERIVED FROM BLOOD SERUM AND CLOT HYPOXIA-CONDITIONED MEDIUM AND METHODS OF THEIR PRODUCTION | May 2019 | May 2023 | Abandon | 49 | 2 | 1 | Yes | No |
| 16345690 | USE OF CONDITIONED MEDIA FROM EXTRACORPOREAL BLOOD DETOXIFYING SYSTEM TO SUPPLEMENT ORGAN PERFUSION SOLUTIONS | April 2019 | January 2025 | Abandon | 60 | 3 | 1 | No | Yes |
| 16390408 | Methods for Generation of Cytocapsulae and Cytocapsular Tubes | April 2019 | July 2021 | Allow | 27 | 3 | 0 | No | No |
| 16335385 | Implantable Device and 3D Bioprinting Methods for Preparing Implantable Device to Deliver Islets of Langerhans | March 2019 | February 2023 | Abandon | 47 | 1 | 1 | No | No |
| 16332634 | BLOOD-BRAIN BARRIER COMPRISING ENGINEERED ENDOTHELIAL CELLS | March 2019 | January 2023 | Allow | 46 | 1 | 0 | No | No |
| 16298957 | DERIVATION AND SELF-RENEWAL OF ISI1+ CELLS AND USES THEREOF | March 2019 | November 2022 | Allow | 44 | 1 | 1 | Yes | No |
| 16330862 | METHOD FOR PRODUCING COLLAGEN HYDROGELS | March 2019 | February 2022 | Allow | 35 | 1 | 1 | No | No |
| 16292114 | METHODS OF REPROGRAMMING CELLS | March 2019 | June 2021 | Allow | 27 | 1 | 1 | Yes | No |
| 16291784 | POSTPARTUM CELLS DERIVED FROM PLACENTAL TISSUE, AND METHODS OF MAKING AND USING THE SAME | March 2019 | January 2021 | Allow | 22 | 2 | 0 | Yes | No |
| 16327402 | STEM CELL-PRODUCED MICROVESICLES FOR TREATING TENDON PATHOLOGIES | February 2019 | October 2022 | Allow | 43 | 1 | 1 | Yes | No |
| 16273712 | LPS PRIMING OF STROMAL CELLS TO GENERATE LPS-SPECIFIC EXOSOME EDUCATED MACROPHAGES | February 2019 | March 2022 | Allow | 37 | 1 | 0 | Yes | No |
| 16272245 | COLLECTION OF AMNIOTIC FLUID FOR WOUND HEALING | February 2019 | August 2021 | Abandon | 30 | 2 | 0 | No | No |
| 16260738 | TISSUE GRAFTS MODIFIED WITH A CROSS-LINKING AGENT AND METHOD OF MAKING AND USING THE SAME | January 2019 | August 2020 | Allow | 19 | 1 | 0 | Yes | No |
| 16260733 | TISSUE GRAFTS MODIFIED WITH A CROSS-LINKING AGENT AND METHOD OF MAKING AND USING THE SAME | January 2019 | August 2020 | Allow | 19 | 1 | 0 | No | No |
| 16321075 | ACELLULAR PLACENTAL PREPARATIONS | January 2019 | July 2024 | Allow | 60 | 4 | 1 | Yes | No |
| 16253026 | BIOACTIVE GRAFTS AND COMPOSITES | January 2019 | October 2023 | Abandon | 57 | 9 | 1 | Yes | No |
| 16252369 | METHODS AND COMPOSITIONS OF CHONDRISOMES | January 2019 | May 2022 | Abandon | 40 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FOX, ALLISON M.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 15.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner FOX, ALLISON M works in Art Unit 1633 and has examined 231 patent applications in our dataset. With an allowance rate of 74.0%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 37 months.
Examiner FOX, ALLISON M's allowance rate of 74.0% places them in the 40% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by FOX, ALLISON M receive 2.33 office actions before reaching final disposition. This places the examiner in the 62% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by FOX, ALLISON M is 37 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +37.5% benefit to allowance rate for applications examined by FOX, ALLISON M. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 24.8% of applications are subsequently allowed. This success rate is in the 40% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 28.6% of cases where such amendments are filed. This entry rate is in the 42% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 63.6% of appeals filed. This is in the 43% percentile among all examiners. Of these withdrawals, 42.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 111.6% are granted (fully or in part). This grant rate is in the 94% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.2% of allowed cases (in the 64% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.